Related Experiment Video

Updated: Nov 17, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.5K

Disseminated BCG Infection after intravesical BCG Immunotherapy of Bladder Cancer

S Ramalingam, K Gunasekaran1, H Arora

  • 1Department of Pulmonary and Critical Care, Pulmonary and Critical Care, Bridgeport Hospital, 267 Grant Street, Bridgeport, CT 06610-5000, USA.

QJM : Monthly Journal of the Association of Physicians
|February 15, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

10.8K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.8K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
860